Navigation Links
Clinical Trial Participation Today May Lead To Future Breakthroughs In Pancreatic Cancer, One Of The Nation's Deadliest Cancers
Date:1/6/2014

MANHATTAN BEACH, Calif., Jan. 6, 2014 /PRNewswire/ -- January marks the annual observance of National Pancreatic Cancer Clinical Trials Awareness Month.  The five year survival rate of pancreatic cancer is just six percent. In the effort to highlight the urgent need to improve the survival rate for this disease, the Pancreatic Cancer Action Network is educating the public about clinical trials and the critical role they play in making scientific progress.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

In particular for pancreatic cancer, with few effective treatment options for patients, clinical trials are an extremely important part of the research process as scientists seek new, better treatments that will ultimately increase survival. Studies have determined that both a lack of awareness and low prioritization of clinical trials by physicians and patients facing cancer contribute to the low enrollment rates.

"Clinical trials are the way to make progress towards better treatments – participation today will shape the treatment landscape for the future," says Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "In addition to being treated with new and innovative therapies, patients will be making a contribution to science by helping researchers learn more about the disease and help improve cancer care."

In 2013, nearly 45,000 Americans were diagnosed with pancreatic cancer and more than 38,000 died from the disease. A recent analysis reveals that pancreatic cancer is projected to move from the fourth to the second leading cause of cancer death in the United States by the year 2020.  Now more than ever, we need to change the course of pancreatic cancer.

"It is also essential for patients to know, that in all pancreatic cancer trials, patients always receive either the best standard treatment or the treatment being evaluated in the trial," adds Fleshman. "Thanks to clinical trial research and participation, significant advancements in the field of pancreatic cancer have been made. However, much still lies ahead."

To bring attention to the need for clinical trials and to increase enrollment, the organization's Patient and Liaison Services (PALS) program educates patients and caregivers about their options and the value of clinical trials. The program also conducts personalized searches using the organization's comprehensive, proprietary clinical trials database to determine potential eligibility. This database is the nation's leading resource for pancreatic cancer clinical trials.

To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org/pals.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Contact:
Anne Milo
Public Relations Manager
Pancreatic Cancer Action Network
Direct: 310-706-3357
Cell: 562-810-3016
Email: amilo@pancan.org

Video with caption: "January is National Pancreatic Cancer Clinical Trials Awareness Month, and you can help make progress in pancreatic cancer by spreading the word about the need for clinical research. With increased research and participation in clinical trials, we can learn faster and improve pancreatic cancer patient outcomes. To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org." Video available at: http://www.youtube.com/watch?v=1Q33kPoZNKM


'/>"/>
SOURCE Pancreatic Cancer Action Network
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TauRx Expands Alzheimers Clinical Trials in the United States
2. ideaPoint, Inc. Announces Launch of Multi-Sponsor Portal Providing Researchers Opportunity to Request Access to Clinical Data from Five Global Study Sponsors
3. Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
4. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
5. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
6. Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
8. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
9. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
10. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
11. Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, the legal cannabis ... to $6.7 billion and can be expected to grow at a 27 ... from $6.7 billion in 2016, to $22.6 billion in 2021. This more ... cannabis without a doctor,s recommendation. Voters in California , ...
(Date:3/27/2017)... /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or ... is pleased to announce it has received conditional approval ... TSX Venture Exchange.  Receiving the conditional ... significant achievements for Invictus-MD. Some of which include: ... Laboratories Inc. ("AB Labs"), a Licensed Producer under the ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates ... National Capital has added 10 new sales professionals over the past 6 months and ... 15 additional new hires over the course of 2017. , “This new office ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to ... responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat ... which proposes a tax on prescription opioids to fund drug rehabilitation and prevention ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce ... large subjects. The ELITE DXA has an active scan window, which is more than ... to fit in the scan area could not undergo an accurate total body bone density ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Digital Scientists, a ... to announce the opening of a Greenville, South Carolina location. The lab ... progress in Greenville. , “We’ve been working with South Carolina clients for years from ...
Breaking Medicine News(10 mins):